TY  - GEN 
AU  - Del Prato, S
AU  - Kang, JH
AU  - Trautmann, ME
AU  - Stewart, J
AU  - Sorli, CH
AU  - Derwahl, M
AU  - Soto Gonzalez, Alfonso
AU  - Yoon, KH
PY  - 2020
SN  - 1462-8902
UR  - http://hdl.handle.net/20.500.11940/16448
AB  - AIMS: To determine the optimal dose(s) of once-monthly administration of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin. MATERIALS AND...
KW  - Drug Therapy
KW  - Humans
KW  - Treatment Outcome
KW  - Hypoglycemic Agents
KW  - Glucagon-Like Peptides
KW  - Proline
KW  - Double-Blind Method
TI  - Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
DO  - 10.1111/dom.14020
KW  - CHUAC
VL  - 22
ER  -